KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2025)

Moderna (MRNA) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $67.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 11.67% to $67.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $215.0 million, a 13.76% increase, with the full-year FY2025 number at $215.0 million, up 13.76% from a year prior.
  • Depreciation & Amortization (CF) was $67.0 million for Q4 2025 at Moderna, up from $52.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $249.0 million in Q3 2023 to a low of $15.0 million in Q1 2021.
  • A 5-year average of $80.2 million and a median of $69.5 million in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 1014.29% in 2021, then crashed 79.12% in 2024.
  • Moderna's Depreciation & Amortization (CF) stood at $78.0 million in 2021, then rose by 2.56% to $80.0 million in 2022, then soared by 152.5% to $202.0 million in 2023, then plummeted by 70.3% to $60.0 million in 2024, then grew by 11.67% to $67.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Depreciation & Amortization (CF) are $67.0 million (Q4 2025), $52.0 million (Q3 2025), and $57.0 million (Q2 2025).